Benzinga · Oct 13, 2026
This Adobe Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Analysts downgraded ACGL, ASTS, PS, LNTH and ADBE, cutting ratings and price targets; ASTS target fell to $54 and Adobe’s to $267.
LN
NASDAQ · LNTH
Lantheus Holdings, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$100.46
Up+$0.14 (+0.14%)
Updated Nov 2, 2026, 3:04 AM
SID Score
5.5/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 4.32B
- P/E ratio
- 25.3
- Dividend yield
- 0.00%
- 52-week range
- $72.35 – $111.86
- Volume
- 476.26K
- Avg. volume
- 1.36M
Price performance · LNTH
LNTH price history
1M range · 0 trading sessions · Daily adjusted prices
LNTH does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest LNTH news
The latest Smart Investors Daily articles mentioning LNTH.
Stock researchCompany · Overview
Company
Market Activity
Research & News
LNTH research
Overview
Company profile and research snapshot.
Company profile
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $78.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 13, 2026 | Mizuho | Neutral | — |
| Aug 4, 2026 | CJS Securities | Market Perform | — |
| Aug 4, 2026 | Truist Securities | Hold | — |
| Aug 3, 2026 | TD Cowen | Hold | — |
| Aug 3, 2026 | William Blair | Market Perform | — |
News briefing
No generated briefing is available yet.
Benzinga · Oct 13, 2026
Mizuho Downgrades Lantheus Holdings to Neutral, Lowers Price Target to $109
Mizuho analyst Anthony Petrone downgrades Lantheus Holdings (NASDAQ:LNTH) from Outperform to Neutral and lowers the price target from $115 to $109.
Yahoo · Sep 26, 2026
Lantheus Holdings (LNTH) Could Be 7% Undervalued On BRAVNETSA Approval
FDA approval for BRAVNETSA puts Lantheus Holdings (LNTH) in focus Lantheus Holdings (LNTH) drew fresh attention after the FDA granted final approval for BRAVNETSA, a radiopharmaceutical considered bioequivalent and therapeutically equivalent to LUTATHERA for adult GEP NET patients. The BRAVNETSA approval lands at a time when Lantheus Holdings has seen short term share price pressure, with the stock down over the past three months. Yet its year to date share price return of 48.27% and 1 year...
Yahoo · Sep 26, 2026
Lantheus Holdings (LNTH) Stock May Be 14% Undervalued On FDA Approval
Lantheus Holdings has delivered a powerful 5 year share price run, and the recent pullback leaves investors asking whether the current US$99.74 level is still grounded in the cash the business can generate. With fresh product news in its core radiopharmaceutical line, the question now is how far those future cash flows can stretch to back up today's valuation. Over the past 5 years the stock has returned 285.5%, which puts real pressure on the cash flow outlook to carry that kind of value...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
